Skip to main content
. 2016 Mar 7;7:10872. doi: 10.1038/ncomms10872

Figure 7. Osteoclast-derived exosomes target osteoblasts.

Figure 7

(a) Representative biophotonic images of the tissue distribution of fluorescence signal in mice at 4 and 8 h after intravenous injection of purified PKH67-labelled exosomes isolated from the supernatant of OC-miR-214-3p osteoclasts (OC-Exo). (b) Representative biophotonic images of the tissue distribution of fluorescence signal in mice at 8 h after intravenous injection of purified PKH67 exosomes isolated from the supernatant of either OC-miR-214-3p osteoclast (OC-Exo) or HEK 293T cells (HEK-Exo). (c) Western blot analysis of the Sema4D protein expression in pellets of sucrose gradient fractions from the osteoclast-derived exosome preparations. The density of each fraction was determined by refraction index measurements. (d,e) Flow cytometry analysis of PKH67+ osteoblasts after incubation with PKH67-labelled exosomes derived from OC-miR-214-3p osteoclasts. The PKH67-labelled exosomes were pre-treated with either anti-Sema4D (20 μg ml−1) or isotype-matched control (Sema4D iso) and then added to osteoblasts for 4 h incubation. (f) Real-time PCR analysis of the levels of pri-miR-214, pre-miR-214 and mature miR-214 in osteoblasts after incubation with either anti-Sema4D-treated exosomes (OC Exo+Anti-Sema4D) or Sema4D isotype-treated exosomes (OC Exo+Sema4D iso), respectively. All data are the mean±s.d. of four independent experiments. *P<0.05. One-way ANOVA with a post-hoc test was performed.